Fecal microbiota transplantation ameliorates atherosclerosis in mice with C1q/TNF-related protein 9 genetic deficiency

Eun Sil Kim1,6, Bo Hyun Yoon1,6, Seung Min Lee1, Min Choi1, Eun Hye Kim1, Byong-Wook Lee1,2, Sang-Yeob Kim1,2, Chan-Gi Pack1,2, Young Hoon Sung1,2, In-Jeoung Baek1,2, Chang Hee Jung3, Tae-Bum Kim4,5, Jin-Yong Jeong1,5,6 and Chang Hoon Ha1,5,6

© The Author(s) 2022

Experimental & Molecular Medicine (2022) 54:103–114; https://doi.org/10.1038/s12276-022-00728-w

Despite the strong influence of the gut microbiota on atherosclerosis, a causal relationship between atherosclerosis pathophysiology and gut microbiota is still unverified. This study was performed to determine the impact of the gut microbiota on the pathogenesis of atherosclerosis caused by genetic deficiency. To elucidate the influence of the gut microbiota on atherosclerosis pathogenesis, an atherosclerosis-prone mouse model (C1q/TNF-related protein 9-knockout (CTRP9-KO) mice) was generated. The gut microbial compositions of CTRP9-KO and WT control mice were compared. Fecal microbiota transplantation (FMT) was performed to confirm the association between gut microbial composition and the progression of atherosclerosis. FMT largely affected the gut microbiota in both CTRP9-KO and WT mice, and all transplanted mice acquired the gut microbiotas of the donor mice. Atherosclerotic lesions in the carotid arteries were decreased in transplanted CTRP9-KO mice compared to CTRP9-KO mice prior to transplantation. Conversely, WT mice transplanted with the gut microbiotas of CTRP9-KO mice showed the opposite effect as that of CTRP9-KO mice transplanted with the gut microbiotas of WT mice. Here, we show that CTRP9 gene deficiency is related to the distribution of the gut microbiota in subjects with atherosclerosis. Transplantation of WT microbiotas into CTRP9-KO mice protected against the progression of atherosclerosis. Conversely, the transplantation of CTRP9-KO microbiotas into WT mice promoted the progression of atherosclerosis. Treating atherosclerosis by restoring gut microbial homeostasis may be an effective therapeutic strategy.

INTRODUCTION

Complex and diverse microbial communities are formed in the human gut to maintain a symbiotic relationship and homeostasis1,2. The gut microbiota has emerged as a critical factor in human health and disease3–5. Evidence to date suggests that changes in the composition and diversity of the gut flora confer a high risk of developing cardiovascular diseases (CVDs), such as arteriosclerosis, hypertension, heart failure, stroke, atrial fibrillation, and myocardial fibrosis6–7.

Atherosclerosis is a chronic inflammatory condition of blood vessels characterized by the infiltration of macrophages, T cells, and other immune cells that, along with cholesterol, form atherosclerotic plaques8–9. Atherosclerotic plaques are influenced by blood shear stress and atheroprotective genes in endothelial cells10. In a previous study of oral and gut samples from patients with atherosclerosis, the abundance of Veillonella and Streptococcus in atherosclerotic plaques correlated with their abundance in the oral cavity, suggesting that the plaque microbiota may correlate with disease markers of atherosclerosis11. Furthermore, patients with symptomatic atherosclerosis had a higher relative abundance of Anaeroglobus in the oral microbiota than asymptomatic atherosclerosis controls12. A previous study of patients with symptomatic atherosclerosis showed that the Collinsella genus was enriched in patients with symptomatic atherosclerosis, whereas Roseburia and Eubacterium were enriched in healthy controls. A previous study also suggested that the gut metagenome may be associated with the inflammatory status of hosts and patients with symptomatic atherosclerosis and may be associated with characteristic changes13.

The gut microbiota may also have an important role in the development of complex metabolic abnormalities in the host that consequently influence the progression of atherosclerotic heart disease. Recent studies have demonstrated that trimethylamine (TMA) and trimethylamine N-oxide (TMAO), which are metabolites derived from the gut microbiota, are associated with CVD and atherosclerosis14,15. Metabolism of dietary L-carnitine, a trimethylamine that is abundant in red meat, by the gut microbiota also produces TMAO and accelerates atherosclerosis in mice16. Bacterial dysbiosis can also influence gut immunity, which increases the risk of atherosclerotic heart disease17. Recent research has revealed that patients with chronic inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, are at increased risk of acute arterial events, and young patients have the highest risk. Disease activity may have an independent impact.
on acute arterial events. However, the composition and functional capacity of the gut microbiome in relation to CVD and atherosclerosis have not been systematically examined. Additionally, it remains unclear how the gut microbiota interacts with CVD in terms of immunity.

In this study, we examined the effects of the gut microbiota on the pathogenesis of atherosclerosis in a transgenic atherosclerosis model with C1q/TNF-related protein 9-knockout (CTRP9-KO) mice. CTRP is an adipokine and an adiponectin family paralog. Members of the CTRP family directly or indirectly play protective roles in the body. CTRP9-KO mice showed altered gut microbial composition and significantly increased cholesterol and LDL levels compared to wild-type control mice. FMT experiments showed that gut microbial composition was significantly associated with the progression of atherosclerosis. The transplantation of WT stools into KO mice protected against the progression of atherosclerosis. The transplantation of KO stools into WT mice promoted the progression of atherosclerosis. In addition, these effects were linked to macrophages. Our results elucidate a critical role of the gut microbiota in atherosclerosis pathogenesis. In other words, genetic variations that affect atherosclerosis alter the composition of the gut microbiome. In addition, altered gut microbial composition affects the progression of atherosclerosis, suggesting that fecal microbiota transplantation may help to prevent atherosclerosis.

**MATERIALS AND METHODS**

**Experimental animals**

All mice were housed in ambient RT (22 ± 1 °C) with 12/12 h light-dark cycles and free access to water and food. Ctrp9-knockout (KO) mice were generated using conventional CRISPR/Cas9 technology, as previously described. Ctrp9-specific guide RNA and Cas9 mRNA were microinjected into the cytoplasm of C57BL/6 N mouse zygotes. The surviving embryos were transferred into the oviducts of synchronized pseudopregnant foster mothers. Genomic DNA samples were prepared from tail biopsies to screen for founder mice with potential targeted mutations in Ctrp9. The selected mutant allele was a 22 bp deletion in Ctrp9 that induced a frame shift mutation. The surviving embryos were washed with serially diluted propylene glycol (60–90%) and stained with 4% paraformaldehyde. Aortas were stained with oil red O (ORO) as described. ORO powder was suspended in propylene glycol at a concentration of 0.4%. After the staining, fixed aortas were symmetrically cut, they were washed with serially diluted propylene glycol (60–90%) and stained with 4% ORO. Fixed carotid artery, right carotid artery, whole aorta, and blood samples were collected to verify atherosclerotic development.

To study arterial morphology, vessels were perfused with PBS. Whole aortas and carotid arteries were rapidly removed, washed in PBS and fixed with 4% paraformaldehyde. Aortas were stained with red oil O (ORO) as described. ORO powder was suspended in propylene glycol at a final concentration of 0.4%. After the fixed aortas were symmetrically cut, they were washed with serially diluted propylene glycol (60–90%) and stained with 0.4% ORO. Fixed carotid artery samples were embedded in paraffin, sectioned at a thickness of 4 μm, and stained with hematoxylin and eosin (H&E).

Fecal microbiota transfer was performed as described by Ericsson et al. Fresh fecal samples were collected from 6-week-old C57BL/6 WT mice and CTRP9-KO mice and stored at −80 °C. All experimental mice were treated with antibiotics (1 g/L ampicillin, 0.5 g/L vancomycin, 1 g/L neomycin, and 1 g/L metronidazole) in their drinking water for 3 weeks. The fecal matter was suspended in PBS and passed through a 30 μm pore nylon filter to remove large particulate and fibrous matter. Fresh fecal slurries were administered intragastrically to recipient mice. FMT was initiated in mice at 9 weeks of age after 3 weeks of antibiotic treatment and was carried out twice per week for a total of 3 weeks. WT mice were inoculated with fecal material derived from CTRP9-KO mice, and CTRP9-KO mice were inoculated with fecal material from WT mice. WT and CTRP9-KO mice that were not inoculated were used as controls.

To assess atherosclerotic pathogenesis, partial carotid ligation was performed as previously described with minor modifications. Briefly, 8-week-old male mice were anesthetized by 2.5% isoflurane inhalation (Piramal Critical Care, Inc. Bethlehem, PA, USA). Then, the left external and internal carotid arterial branches were ligated with 6-0 silk sutures. After ligation, the mice were fed a high-fat diet (HFD; D12336, Research Diets, Inc., NJ, USA) to maximize atherosclerosis development. Three weeks later, the left carotid artery, right carotid artery, whole aorta, and blood samples were collected to verify atherosclerotic development.

**Cross-transplantation of fecal microbiota**

**Biological analysis of blood samples**

Blood samples were obtained from the vena cava before sacrifice and centrifuged at 3500 × g for 10 min at 4 °C. Total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) were measured by a blood biochemical analyzer (Hitachi 7180, Hitachi, Tokyo, Japan).

Experimental & Molecular Medicine (2022) 54:103 – 114

**DNA extraction and bacterial metagenomic analysis**

Fecal metagenomic DNA was extracted using a DNA isolation kit (QIAxpert system, QIAGEN, Germany). The 16 S rRNA gene targeting V3–V4 of the variable region was amplified with 16S_V3_F (5′- TCCTTGAGACCTTGCAGCTCGATAGTGTTATAAGAGACGCTTACGGGNGGCWGCAG-3′) and 16S_V4_R (5′-GTCTCCTGCTGGCTCAGGTGAAGATGTATAAAGAGACGACTACHVGGGTATCTAACTC-3′) primers. Libraries were prepared using PCR products according to the MiSeq System guide (illumina, USA) and quantified using QIAxpert (QIAGEN, Germany). Each amplicon was then quantified, set at an equimolar ratio, pooled, and sequenced on a MiSeq instrument (illumina, USA) according to the manufacturer’s recommendations.

**Immunofluorescence staining**

Immunofluorescence staining was performed using α-SMA (ab5694, Abcam, Cambridge, MA, USA), CD31 (Abcam, Cambridge, MA, USA), CD45 (550539, BD Pharm., San Jose, CA, USA), CD3 (A0452, Dako, Santa Clara, CA, USA), CD19 (14-0194-82, Thermo, Waltham, MA, USA), CD68 (ab125212, Abcam, Cambridge, MA, USA), and Sca-1 (AP1226, R&D Systems, Minneapolis, MN, USA) primary antibodies. Anti-rabbit AF546, anti-mouse AF488, and anti-rat AF594 secondary antibodies were used, and DAPI (Molecular Probes, Eugene, OR, USA) was used to stain the nucleus. Mounted tissue slides were photographed using an LSM 780 laser scanning microscope (Carl Zeiss, Germany). Intensity profiles were analyzed using ZEN 2.6 (blue edition) software.
RESULTS

Construction of atherosclerosis-prone CTRP9-KO mice

To determine the functional consequences of CTRP9 gene disruption, a partial carotid ligation model was used to evaluate the effects on atherosclerosis progression, and the mice were fed a HFD for three weeks. HFD-fed CTRP9-KO mice had elevated levels of serum cholesterol and low-density lipoprotein compared to WT mice (Fig. 1a–c), while TG and high-density lipoprotein levels were not significantly different (Fig. 1d, e). To identify more evidence of the atherogenic effects of CTRP9 deficiency, histologic analysis of the left carotid artery (LCA) was performed. At 3 weeks after LCA partial ligation and HFD feeding, neointima formation and luminal narrowing were significantly induced in CTRP9-KO mice (Fig. 1f). Collectively, these results indicate that CTRP9 plays a crucial role in atherosclerosis progression.

Alterations in the gut microbial community resulting from CTRP9 gene deficiency

To explore whether the development of atherosclerosis was associated with intestinal dysbiosis, the gut metagenomic profile of atherosclerosis-prone CTRP9-KO mice was compared to that of WT mice at 6 weeks. To assess how each genotype affects the gut microbial profile, alpha- and beta-diversity were compared to assess microbial diversity in these two groups. Alpha diversity was analyzed by calculating Shannon’s index (a proxy for diversity) and Chao1 (a proxy for richness). There were significant differences in bacterial diversity and richness between CTRP9-KO and WT mice (Fig. 2a). Shannon’s diversity, which is an indirect measure of evenness, was significantly lower in the CTRP9-KO group than in the WT group (Kruskal-Wallis test, \( p = 0.002 \)). Chao1 richness was significantly higher in WT mice than in CTRP9-KO mice (Kruskal-Wallis test, \( p = 0.015 \)). Next, the beta diversity in the two groups was analyzed using Bray-Curtis (qualitative measure) and Jaccard distances (quantitative measure) (Fig. 2b). The gut microbiota of CTRP9-KO mice was different from that of WT mice in terms of qualitative (\( p < 0.001 \)) and quantitative measures (\( p < 0.001 \)) of bacterial clustering, indicating that CTRP9-KO mice have an altered gut microbial community. These observations suggest that alterations in the gut microbiota could be attributed to changes in the CTRP9 gene.

Next, the percentage of bacterial taxa differentiating the gut microbiota of CTRP9-KO and WT mice was calculated using a linear discriminant analysis effect size (LEfSe) method (Fig. 2c, d). Different profiles were noted for CTRP9-KO and WT mice. The most abundant phylum was Firmicutes (68.38%; 95% CI, 62.47–73.73%) in WT mice, but Bacteroidetes (62.38%; 95% CI, 50.82–74.53%) was the most abundant phylum in CTRP9-KO mice (Fig. 2c). The taxonomy of the phyla of gut microbiota in CTRP9-KO and WT mice is summarized in Supplementary Table 1. The bacterial diversity of WT mice was slightly higher than that of CTRP9-KO mice. The Ruminococcaceae family of phylum Firmicutes was the most frequent (45.64%) among the gut microbiota of WT mice, and the Bacteroidaceae family of phylum Bacteroidetes was 28.99%. In CTRP9-KO mice, the Bacteroidales family S24-7 group of phylum Bacteroidetes was the most frequent (51.15%), followed by an unknown (12.60%) family from phylum Saccharibacteria (Table 1). The dominant gut microbiota were identified in WT and CTRP9-KO mice.

FMT altered the composition of the gut microbiota in CTRP9-KO and WT mice

To clarify the association between alterations in the gut microbiota and the pathogenesis of atherosclerosis, FMT was performed in the two groups of mice (Fig. 3a). First, WT mice were used as donors, and CTRP9-KO mice were used as recipients. Next, the fecal microbiota of CTRP9-KO mice was transplanted to WT mouse recipients. FMT effectiveness was evaluated by comparing the gut microbiota profiles of recipient, transplanted, and donor mice. FMT largely affected the gut microbiota of CTRP9-KO and WT mice, and all transplanted mice acquired the gut microbiota of donor mice (Fig. 3b). The composition of the gut microbiota in FMT mice was significantly changed after 3 weeks of FMT (\( P < 0.05 \)). CTRP9-KO mice that were transplanted with the gut microbiota of WT mice showed a significant increase in Firmicutes from 27.13% to 38.42% compared to that in recipient mice, whereas Bacteroidetes decreased from 57.63% to 25.73%. In WT mice transplanted with the CTRP9-KO gut microbiota, Bacteroidetes increased from 37.88% to 48.91% and Firmicutes decreased from 47.70% to 32.11%. The most frequent family in WT mice, Ruminococcaceae, increased from 6.67% to 9.46% in CTRP9-KO mice after the mice were transplanted with the WT gut microbiota, while the most frequent family in CTRP9-KO mice, Bacteroidales S24-7 group, decreased significantly from 45.57% to 18.97%. In WT mice transplanted with the CTRP9-KO gut microbiota, the f_Bacteroidales S24-7 group increased from 26.19% to 37.62% (\( p < 0.001 \)), while f_Ruminococcaceae decreased significantly from 10.53% to 4.10% (\( p < 0.001 \)) (Fig. 3c).

Transplantation with WT gut microbiota ameliorated atherosclerosis in CTRP9-KO mice

Based on these results, we verified the effectiveness of FMT administered by oral injection. To examine the effects of FMT on atherosclerosis progression in detail, a partial carotid ligation model was used to evaluate the transplantation of the gut microbiota in vivo, as described in the Methods. Serum lipid levels in WT and CTRP9-KO mice were the same as those shown in Fig. 1a–e. In WT mice that were transplanted with the microbiota from CTRP9-KO mice, cholesterol and LDL levels were noticeably increased (Fig. 3d, f, and h), similar to those of CTRP9-KO mice, but TG and HDL levels were not significantly altered (Fig. 3e, g). In CTRP9-KO mice that were transplanted with the microbiota of WT mice, cholesterol and LDL levels were substantially decreased, while TG levels were decreased more than those in the WT group (Fig. 3d, f).

Histologic analysis was used to further examine the effect of microbiota transplantation on atherosclerosis progression. The carotid arteries were isolated, and a paraffin block was produced. H&E staining of carotid artery sections was used to measure neointima formation and luminal narrowing (Fig. 4a, b). As expected, CTRP9-KO mice had significantly more atherosclerotic lesions than WT mice. Atherosclerotic lesions in the carotid arteries were increased in WT mice with FMT more than in WT mice without FMT, while lesions were decreased in CTRP9-KO mice with FMT more than in CTRP9-KO mice without FMT. Moreover, CTRP9-KO mice with FMT showed decreased carotid luminal narrowing compared to WT mice (Fig. 4b).

Immunofluorescence staining of CD31 and SMA showed the same results: significant proliferation in the media and neointima in WT mice with FMT and CTRP9-KO mice without FMT but not in WT mice without FMT or CTRP9-KO mice with FMT (Fig. 4a). To obtain additional evidence of effect of fecal microbiota transfer on atherosclerotic lesions in WT and CTRP9-KO mice, whole aortas from HFD-fed WT and CTRP9-KO mice with or without FMT were stained en face with oil red O (ORO). Quantitative analysis revealed statistically significant numbers of lesions. Atherosclerotic lesions were increased in WT mice with FMT and decreased in CTRP9-KO mice with FMT (Fig. 4c, d). To summarize the results thus far, the data showed the same pattern in which CTRP9-KO mice had increased atherosclerosis progression compared to WT mice, while microbiota transfer resulted in the opposite effects. Symptoms were exacerbated by treatment with KO stool, while treatment with WT stool relieved symptoms. These interesting results indicate that CTRP9-KO mice are an effective animal model for atherosclerosis studies, and the transfer of fecal microbiota between WT mice and CTRP9-KO mice showed a useful therapeutic effect on atherosclerosis.

Statistical analysis

All data are presented as the mean ± SD of at least three independent experiments for a given sample. Two-tailed Student’s t test was used for comparisons between two groups. \( P \) values < 0.05 were deemed significant.
Fig. 1  Construction of atherosclerosis-prone CTRP9-KO mice.  

a–e Serum profiles of cholesterol, TG, LDL, HDL, and the LDL/HDL ratio in WT and CTRP9-KO mice.  

f  Representative micrographs of H&E-stained carotid artery lesions 3 weeks after partial ligation and HFD feeding. Scale bars in right lower corner represent 50 μm.
Fig. 2 Alterations in gut microbiota composition in CTRP9-KO mice with atherosclerosis. The V3-V4 region of bacterial 16S rRNA was sequenced in fecal samples from 6-week-old CTRP9-KO (n = 6) and WT (n = 6) mice. a Alpha diversity analysis based on Shannon’s index (proxy for diversity) and Chao1 (proxy for richness) at the phylum level. b Beta-diversity analysis based on Bray–Curtis (qualitative measure) and Jaccard distances (quantitative measure). c Relative abundance of the total gut microbiota at the phylum level in CTRP9-KO and WT mice. d Percentage of bacterial taxa discriminating the gut microbiota in CTRP9-KO and WT mice.
Table 1. Distinct gut microbiota compositions in CTRP9-KO and WT mice.

| Phylum     | Family                  | Abundance (%) | P values | LDA score | Genus                  | Abundance (%) | P value | LDA score |
|------------|-------------------------|---------------|----------|-----------|-------------------------|---------------|---------|-----------|
|            |                         | WT            | CTRP9-KO |           |                         |               |         |           |
| Firmicutes | f_Ruminococcaceae       | 45.64         | 3.89     | 0.004     | g_Ruminococcaceae       | 28.68         | 1.83    | 0.002     |
|            |                         |               |          |           | UCG-014                 | 28.68         | 1.83    | 0.002     |
|            |                         |               |          |           | g_Ruminococcus 1        | 2.34          | 0.02    | 0.002     |
|            |                         |               |          |           | g_uncultured            | 2.15          | 0.19    | 0.002     |
|            |                         |               |          |           | g_Ruminococcaceae       | 0.52          | 0.05    | 0.002     |
|            |                         |               |          |           | UCG-003                 | 0.18          | 0.05    | 0.009     |
|            |                         |               |          |           | g_Ruminiclostridium_5   | 0.31          | 0.12    | 0.026     |
|            |                         |               |          |           | g_Ruminiclostridium_6   | 0.17          | 0.004   | 0.044     |
|            |                         |               |          |           | g_Ruminiclostridium     | 0.20          | 0.07    | 0.041     |
|            | f_Peptococcaceae        | 0.75          | 0.04     | 0.004     | g_uncultured            | 0.73          | 0.04    | 0.002     |
| Bacteroides| f_Bacteroidaceae        | 28.99         | 1.05     | 0.004     | g_Bacteroides           | 28.99         | 1.05    | 0.002     |
|            | f_Porphyromonadaceae    | 0.77          | 0.07     | 0.004     | g_Parabacteroides       | 0.76          | 0.05    | 0.002     |
|            |                         | 0.10          | 51.15    | 0.004     | g_uncultured bacterium  | 0.10          | 50.52   | 0.002     |
|            |                         |               |          |           |                         |               |         |           |
| f_Bacteroidales S24-7 group |                 |               |          |           |                         |               |         |           |
|            | f_Prevotellaceae        | 0             | 5.76     | 0.002     | g_Prevotella 9          | 0             | 4.48    | 0.003     |
|            |                         |               |          |           | g_Prevotellaceae UCG-001| 0             | 1.28    | 0.003     |
|            | f_Rikenellaceae         | 0.001         | 4.35     | 0.003     | g_Rikenella            | 0             | 1.12    | 0.003     |
| Proteobacteria | f_Alcaligenaceae    | 0.001         | 0.94     | 0.003     | Parasutterella          | 0.001         | 0.94    | 0.004     |
|            | f_Desulfovibrionaceae  | 0             | 1.85     | 0.002     | Desulfovibrio           | 0             | 1.81    | 0.003     |
|            |                         |               |          |           | Bilophila               | 0             | 0.04    | 0.003     |
| Saccharibacteria | f_Unknown_Family       | 0.004         | 12.60    | 0.004     | Candidatus Saccharimonas| 0.004         | 12.60   | 0.005     |
| Verrucomicrobia | f_Verrucomicrobiaceae | 0.39          | 0.001    | 0.146     | Akkermansia             | 0.39          | 0.001   | 0.146     |

Analyses were performed on WT ($n=6$) and CTRP9-KO ($n=6$) mice. The data are presented as the mean percentages and LDA scores. A nonparametric Wilcoxon test was used to compare two independent groups.
The vasa vasorum plays a crucial role in the accumulation of immune cells and atherosclerosis progression in CTRP9-deficient mice. Thus far, we have shown that the adipokine CTRP9 plays an important role in atherosclerosis progression and that FMT can protect against the progression of atherosclerosis. Next, we further examined angiogenesis in the affected adventitial vasa vasorum and the distribution of the immune cell populations in atherosclerotic lesions after fecal microbiota transfer between CTRP9-KO and WT mice.
The adventitial vasa vasorum was identified as CD45 + Sca-1+ cells in the atherosclerotic aorta (Fig. 5a, b). The vasa vasorum plays a role in blood supply and nourishment for the tunica adventitia and outer parts of the tunica media in large veins and arteries. A previous report showed that CD45 + Sca-1+ cells are vasculogenic and that the vasa vasorum plays a role in the development of atherosclerosis.24 Double staining with CD45 and Sca-1 was performed. Cells forming the vessel were completely stained with CD45 and Sca-1 to identify the vasa vasorum. The number of vasa vasorum vessels was significantly increased in CTRP9-KO mice without FMT and WT mice with FMT compared to WT mice without FMT and CTRP9-KO mice with FMT (Fig. 5a, b). These findings suggest that vasa vasorum pathology plays an important role in atherosclerosis progression due to CTRP9 deficiency. In addition, the exchange of the gut microbiota from WT mice by FMT restored the function of the vasa vasorum.

Next, the populations of B cells, T cells, and macrophages were examined to identify the immune cells involved in atherosclerosis progression due to CTRP9 deficiency (Fig. 6c–h). Variations in the total numbers of macrophages and lymphocytes were significantly increased in CTRP9-KO mice and were restored by FMT. The intestinal lamina has autofluorescence that can be detected in green channels. Therefore, WT and CTRP9-KO mice with FMT were distinguished by the intestinal lamina, while CTRP9-KO and WT mice with FMT were impossible to distinguish because of broken boundaries. Interestingly, stained cells were clustered between the adventitia and media. Variations in macrophages were significantly different in each group, while T cells were altered in the media and neointima in CTRP9-KO mice with and without FMT. Macrophages were significantly increased in the adventitia, media, and neointima in CTRP9-KO mice and WT mice with FMT compared to WT mice. The score of CTRP9-KO mice more than doubled compared to that of WT mice, but that of CTRP9-KO mice with FMT decreased more than that of the other group (Fig. 6g, h). Finally, the number of macrophages was measured and varied significantly in each group. Furthermore, macrophages were significantly increased in the adventitia, media, and neointima in the KO group and in WT mice with FMT compared to WT mice. However, the number of cells per unit area was not significantly different in the neointimal region. These results indicate that CTRP9-mediated atherosclerotic lesions were associated with the distribution of immune cells resulting from adventitial vasa vasorum angiogenesis.

### DISCUSSION

In the present study, we investigated the potential effect of the gut microbiota on atherosclerosis pathogenesis. This study reveals that alterations in the composition of the gut microbiota in CTRP9-KO mice strongly influence atherosclerosis pathogenesis. Gut-associated pathogenesis has been strongly linked to the populations of various immune cells, including macrophages, T cells, B cells, and lymphocytes.

A substantial number of studies has provided evidence for the role of the gut microbiota in human diseases, including CVD. In animal studies, successful transplantation of certain bacteria has successfully reduced atherosclerosis in mice.35,36 The probiotic bacterium Akkermansia muciniphila attenuates atherosclerotic lesions by improving metabolic endotoxemia-induced inflammation by restoring the gut barrier.35,36 Two other dominant species of the genus Bacteroides in the human gut microbiota, Bacteroides vulgatus and Bacteroides dorei, have also been shown to attenuate the formation of atherosclerotic lesions in atherosclerosis-prone mice, markedly ameliorating endotoxemia, decreasing gut microbial lipopolysaccharide production, and effectively suppressing proinflammatory immune responses.36,37 Akkermansia muciniphila, B. vulgatus, and B. dorei did not show any differences between WT and KO mice in this study. This is probably due to differences in the relative abundances of the dominant gut microbiota in mice and humans. This result may also be due to deficiency of the CTRP9 gene.

In this study, a CTRP9-KO mouse model was used to investigate the relationship between the gut microbiome and atherosclerosis. An adiponectin family paralog has been uncovered and designated C1q/TNF-related protein (CTRP). Members of the CTRP family directly or indirectly play protective roles in regulating the inflammatory cascade and the immune and cardiovascular systems.19,22 Compared with other family members, CTRP9 has been the subject of more published research concerning CVD. Previous studies showed genetic evidence for a physiological role of CTRP9, suggesting that CTRP9 may play a significant role in cardiovascular homeostasis.23,24 CTRP9 also promotes endothelial cell function and improves endothelium-dependent vasorelaxation.25 Recently, others have shown that plasma levels of CTRP9 are reduced in obese mice.25,26

CTRP9 exerts a protective effect by stimulating eNOS phosphorylation and nitric oxide production in endothelial cells and reduces neointimal formation in a mouse model of vascular injury.25,37,38 The composition of the gut microbiota in CTRP9-KO mice differed from that of WT mice at 6 weeks of age in this study, suggesting that alterations in the composition of the gut microbiota in CTRP9-KO mice may be due to transgenic modifications leading to loss of the CTRP9 gene. The most abundant phylum in CTRP9-KO mice was Firmicutes, whereas Bacteroidetes was the most abundant phylum in WT mice (Fig. 2c, d). Few discriminant bacterial taxa were detected in CTRP9-KO mice (Table 1). The bacterial diversity of CTRP9-KO mice was also slightly higher than that of WT mice (Fig. 2c). These observations suggest that community-level alterations in the gut microbiota rather than changes in a single bacterial taxon may be associated with the development of atherosclerosis in CTRP9-KO mice. This change in the gut environment of CTRP9-KO mice has been shown to significantly reduce cholesterol, LDL, and TG levels. The present study used 16S rRNA sequencing analysis and did not
Fig. 4  Amelioration of atherosclerosis in CTRP9-KO mice transplanted with the WT gut microbiota. a Representative micrographs of H&E-
stained carotid lesions 3 weeks after partial ligation and HFD feeding. Sham, sham surgery group; ligation, ligation surgery group. Squares
indicate areas shown at higher-power magnification of the respective cross-sections. Representative images showing immunofluorescence
staining of PECAM-1 and α-SMA in carotid lesions. b Micrographs were quantified using ImageJ software. c Atherosclerotic plaques in the
aorta were stained en face with oil red O. Representative en face view of the aortic surface area covered by lesions after 3 weeks of partial
ligation and HFD feeding. d Micrographs were quantified using ImageJ software. Error bar indicates the SD (n = 3). The results show the mean
± SD. *p < 0.05 for the WT-FMT group and KO group compared to the WT group. #p < 0.05 for the KO-FMT group compared to the KO group.
All group comparisons were performed with t test. Scale bars in right lower corner represent 50 μm.
identify which specific species were associated with atherosclerosis due to limited discriminatory abilities for some genera.

It is worth noting that FMT-induced modifications in the gut microbiota in CTRP9-KO mice appeared to ameliorate the etiology of atherosclerosis. FMT greatly influenced the composition of the gut microbiota in CTRP9-KO mice. As shown in the gut environment of WT mice, Firmicutes was greatly increased and Bacteroidetes was greatly decreased by FMT (Fig. 3b, c). This study demonstrates that FMT is an effective way to control the gut environment. FMT is also useful in studying the association of microbial communities with atherosclerosis pathogenesis. To confirm that the changes in the composition of immune cells in atherosclerotic lesions depend on alterations in gut microbial communities, angiogenesis in the adventitial vasa vasorum was

---

**Fig. 5 Adventitial vasa vasorum contains CD45^+ Sca-1^+ cells in the atherosclerotic aorta.** a, b Vasa vasorum staining with CD45 and Sca-1. White arrows indicate the vasa vasorum, *p < 0.05 the KO-FMT group compared to the KO group. Two-way comparisons were performed with t tests. Scale bars in right lower corner represent 50 μm.
WT mice without FMT and CTRP9-KO mice with FMT. These findings suggest that the pathologic vasa vasorum plays an important role in atherosclerosis progression resulting from CTRP9 deficiency, and the exchange of the gut microbiota in WT mice by FMT rescued the pathologic vasa vasorum. The number of each type of immune cell during the progression of atherosclerotic lesions was increased in CTRP9-KO mice and WT mice with FMT. These results indicate that atherosclerosis due to CTRP9 deficiency causes the accumulation of various immune cells through pathologic vasa vasorum angiogenesis. Variations in the total numbers of macrophages and lymphocytes were significantly increased in CTRP9-KO mice and were restored by FMT. Macrophages are central in the development of atherosclerosis, as they absorb deposited lipoprotein and amplify local inflammation. Previous studies have shown that C1q/TNF-related proteins (CTRPs) play various roles in vascular functions, such as the inflammatory responses of macrophages. CTRP9 exerts its biological effects through AdipoR1 and AdipoR2. Additionally, several groups have reported the expression of the adiponectin receptors adipor1 and AdipoR2 in the colonic epithelium.

In humans, imbalances in the composition of the gut microbiome are independent risk factors for atherosclerosis, but microbiome-environment interactions and the pathogenetic mechanisms involved remain unclear. Further studies are needed to evaluate the use of immune-targeted therapies for atherosclerotic cardiovascular disease.

In this study, we showed that mutations in the genetic background can alter the composition of the gut microbiome and result in atherosclerosis. In addition, FMT using healthy donor stool can protect against this disease in CTRP9-deficient mice. Our results indicate the possibility of controlling gut microbial composition to treat arteriosclerosis caused by genetic deficiency. FMT may be an attractive therapeutic strategy for atherosclerosis.

REFERENCES

1. Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).
2. Eckburg, P. B. et al. Diversity of the human intestinal microbial flora. Science 308, 1635–1638 (2005).
3. Clemente, J. C., Ursell, L. K., Parfrey, L. W. & Knight, R. The impact of the gut microbiota on human health: an integrative view. Cell 148, 1258–1270 (2012).
4. Wang, J. & Jia, H. Metagenome-wide association studies: fine-mining the microbiome. Nat. Rev. Microbiol. 14, 508–522 (2016).
5. Dabke, K., Hendrick, G. & Devkota, S. The gut microbiome and metabolic syndrome. J. Clin. Invest. 129, 4050–4057 (2019).
6. Aron-Wisnewsky, J. & Clement, K. The gut microbiome, diet, and links to cardiovascular disease. Nat. Rev. Nephrol. 12, 169–181 (2016).
7. Tang, W. H., Kitai, T. & Hazen, S. L. Gut microbiota in cardiovascular health and disease. Circ. Res. 120, 1183–1196 (2017).
8. Dahlöf, B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am. J. Cardiol. 105, 3A–9A (2010).
9. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685–1695 (2005).
10. Gimbrone, M. A. Jr., Topper, J. N., Nagel, T., Anderson, K. R. & Garcia-Cardenas, G. Endothelial dysfunction, hemodynamic forces, and arterogenesis. Ann. N.Y. Acad. Sci. 902, 230–239 (2000). discussion 239-240.
11. Koren, O. et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc. Natl Acad. Sci. USA 108, 4592–4598 (2011). Suppl 1.
12. Fak, F., Tremaroli, V., Bergstrom, G. & Backhed, F. Oral microbiota in patients with atherosclerosis. *Atherosclerosis* **243**, 573–578 (2015).

13. Karlsson, F. H. et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. *Nat. Commun.* **3**, 1245 (2012).

14. Tang, W. H. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N. Engl. J. Med.* **368**, 1575–1584 (2013).

15. Lerandi, E. et al. Intestinal microbial metabolism of phosphatidylcholine: a novel insight in the cardiovascular risk scenario. *Hepatobiliary. Surg. Nutr.* **4**, 289–292 (2015).

16. Koeth, R. A. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. *Nat. Med.* **19**, 576–583 (2013).

17. Yamashita, T. Intestinal Immunity and Gut Microbiota in Atherosclerosis. *J. Atheroscler. Thromb.* **24**, 110–119 (2017).

18. Kirchgesner, J. et al. Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. *Gut* **67**, 1261–1268 (2018).

19. Wong, G. W., Wang, J., Hug, C., Tsao, T. S. & Lodish, H. F. A family of Acrp30/adiponectin structural and functional paralogs. *Proc. Natl. Acad. Sci.* **101**, 10302–10307 (2004).

20. Wong, G. W. et al. Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. *Biochem. J.* **416**, 161–177 (2008).

21. Peterson, J. M., Aja, S., Wei, Z. & Wong, G. W. CTRP1 protein enhances fatty acid oxidation via AMP-activated protein kinase (AMPK) activation and acetyl-CoA carboxylase (ACC) inhibition. *J. Biol. Chem.* **287**, 1576–1587 (2012).

22. Liu, L. et al. C1q/TNF-related protein-1: an adipokine marking and promoting atherosclerosis. *Eur. Heart J.* **37**, 1762–1771 (2016).

23. Yi, W. et al. Reduced cardioprotective action of adiponectin in high-fat diet-induced type II diabetic mice and its underlying mechanisms. *Antioxid. Redox Signal.* **15**, 1779–1788 (2011).

24. Su, H. et al. Inhibition of CTRP9, a novel and cardiac-abundantly expressed cell survival molecule, by TNFalpha-initiated oxidative signaling contributes to exacerbated cardiac injury in diabetic mice. *Basic. Res. Cardiol.* **108**, 315 (2013).

25. Zheng, Q. et al. C1q/TNF-related proteins, a family of novel adipokines, induce vascular relaxation through the adiponectin receptor-1/AMPK/eNOS/nitric oxide signaling pathway. *Arterioscler. Thromb. Vasc. Biol.* **31**, 2616–2623 (2011).

26. Wang, H. et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* **153**, 910–918 (2013).

27. Kwon, S., Lee, B. & Yoon, S. CASPER: context-aware scheme for paired-end reads from high-throughput amplicon sequencing. *BMC Bioinform.* **15**, S10 (2014). Suppl 9.

28. Bokulič, N. A. et al. Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing. *Nat. Methods* **10**, 57–59 (2013).

29. Rogens, T., Flouri, T., Nichols, B., Quince, C. & Mahe, F. VSEARCH: a versatile open source tool for metagenomics. *PeerJ* 4, e2584 (2016).

30. Quast, C. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. *Nucleic Acids Res.* **41**, D590–D596 (2013).

31. Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. *Nat. Methods* **7**, 335–336 (2010).

32. Ericsson, A. C., Personett, A. R., Turner, G., Dorfmeier, R. A. & Franklin, C. L. Variable colonization after reciprocal fecal microbiota transfer between mice with low and high richness microbiota. *Front. Microbiol.* **8**, 196 (2017).

33. Nam, D. et al. Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. *Am. J. Physiol. Heart Circ. Physiol.* **297**, H1535–H1543 (2009).

34. Toledo-Flores, D. et al. Vascularogenic properties of adventitial Sca-1(+)/CD45(+) progenitor cells in mice: a potential source of vasa vasorum in atherosclerosis. *Sci. Rep.* **9**, 7286 (2019).

35. Li, J., Lin, S., Vanhoucke, P. M., Woo, C. W. & Xu, A. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in ApoE−/− mice. *Circulation* **133**, 2434–2446 (2016).

36. Yoshida, N. et al. Bacteroides vulgatus and Bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. *Circulation* **138**, 2486–2498 (2018).

37. Jung, C. H. et al. C1q/TNF-related protein-9 inhibits cytokine-induced vascular inflammation and leukocyte adhesiveness via AMP-activated protein kinase activation in endothelial cells. *Mol. Cell. Endocrinol.* **419**, 235–244 (2016).

38. Wong, G. W. et al. Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin. *FASEB J.* **23**, 241–258 (2009).

39. Wang, X. Q. et al. C1q/TNF-related protein 1 links macrophage lipid metabolism to inflammation and atherosclerosis. *Atherosclerosis* **250**, 38–45 (2016).

40. Libby, P., Ridker, P. M. & Maseri, A. Inflammation and atherosclerosis. *Circulation* **105**, 1135–1143 (2002).

41. Hug, C. et al. T-cadherin is a receptor for hexamerich and high-molecular-weight forms of Acrp30/adiponectin. *Proc. Natl. Acad. Sci. USA* **101**, 10308–10313 (2004).

42. Kambara, T. et al. C1q/tumor necrosis factor-related protein 9 protects against acute myocardial injury through an adiponectin receptor-1/AMPK-dependent mechanism. *Mol. Cell. Biol.* **35**, 2173–2185 (2015).

43. Yoneda, K. et al. Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal colon epithelium and colon cancer tissue. *Oncol. Rep.* **20**, 479–483 (2008).

ACKNOWLEDGEMENTS

We thank the Confocal Microscopy Core Facility and the Comparative Pathology Core at the ConvergeXe mEdicine research cEnTer (CREDIT), Asan Medical Center for support and instrumentation. This research was supported by National Research Foundation of Korea (NRF) grants (NRF-2020R1I1A2072110, 2021R1A6A1A03040260, 2021R1I1A1A01051203). This work was also supported by grants (2018IP0348, 2018IP0687, 2020IP0011) from the Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s12276-022-00728-w.

Correspondence and requests for materials should be addressed to Tae-Bum Kim, Jin-Yong Jeong or Chang Hoon Ha.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022